Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06796998 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
A Phase 2 study of Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, sponsored by Izidore Lossos, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06796998: Recruiting Phase 2 study of Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, sponsored by Izidore Lossos, MD.
NCT06796998 is a Phase 2 study of Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue that is actively recruiting participants, run by Izidore Lossos, MD. The registered enrollment target is 25 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06796998, a Phase 2 study of Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, is actively recruiting participants, sponsored by Izidore Lossos, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
Primary Outcome
The proportion of participants achieving a best overall response of complete response (CR) after Cycle 12 of study therapy will be reported. Response will be assessed using modified Cheson criteria, if disease is not fluorodeoxyglucose (FDG)-avid in initial Screening; or by revised Lugano criteria if Screening FDG-positron emission tomography (PET)/ computed tomography (CT) demonstrated FDG avid disease. For Lugano criteria, CR will be defined by a Deauville score of ≤3.
Conditions Studied
Interventions
- BIOLOGICAL Epcoritamab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2031-04-15 |
| Phase | Phase 2 |
What NCT06796998 shows while recruiting
NCT06796998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (75% lower).
The record links to 4 conditions, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06796998 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06796998 about?
NCT06796998 is a clinical study titled "Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)". The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
What is the current status of trial NCT06796998?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-10-13. Estimated completion is 2031-04-15.
What conditions does trial NCT06796998 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma.
What interventions are being tested in trial NCT06796998?
The interventions under investigation include: Epcoritamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06796998?
This trial is sponsored by Izidore Lossos, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06796998 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06796998's enrollment target sits among peer trials
25 41st of 49 higher than 9 of 49 other Marginal Zone Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Marginal Zone Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RECRUITING · Phase 2
-
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI